A Guide to the New Medicare Cost Savings in 2026
If you’ve heard about new ways to save on Medicare starting in 2026, you’re in the right place. Significant changes are on the horizon that could lower your healthcare costs, particularly for prescription drugs. This guide breaks down exactly what these new “discounts” are, how they work, and who is eligible.
What Are the Big Medicare Changes for 2026?
The new cost-saving measures coming to Medicare are not traditional coupons or limited-time offers. They are fundamental changes to how Medicare Part D (the prescription drug program) works, thanks to the Inflation Reduction Act. The goal is to make prescription drugs more affordable and predictable for millions of Americans.
The two most significant changes that will be fully active in 2026 are the Medicare Drug Price Negotiation Program and a cap on out-of-pocket drug spending. Let’s explore each one in detail.
The First-Ever Medicare Drug Price Negotiation
For the first time, Medicare will be able to directly negotiate the prices of certain high-cost prescription drugs with manufacturers. This is a landmark change designed to lower drug costs for both beneficiaries and the government.
How It Works
The process started in 2023 when the Centers for Medicare & Medicaid Services (CMS) selected the first 10 drugs for negotiation. These drugs were chosen because they are widely used by beneficiaries and account for a significant portion of Medicare spending, but they do not have generic or biosimilar competition.
After a year-long negotiation process with the drug makers, the new, lower prices for these specific medications will take effect on January 1, 2026.
The First 10 Drugs with Negotiated Prices in 2026
Knowing which drugs are included is key to understanding if you will benefit. If you take any of the following medications, you will likely see lower costs in 2026.
The first 10 drugs selected for price negotiation are:
- Eliquis: Used to prevent blood clots.
- Jardiance: Used to treat type 2 diabetes and heart failure.
- Xarelto: Another medication used to prevent blood clots.
- Januvia: Used to treat type 2 diabetes.
- Farxiga: Used for type 2 diabetes, heart failure, and chronic kidney disease.
- Entresto: Used to treat heart failure.
- Enbrel: Used to treat rheumatoid arthritis and other autoimmune conditions.
- Imbruvica: A treatment for certain types of blood cancers.
- Stelara: Used for psoriasis, Crohn’s disease, and ulcerative colitis.
- Fiasp; NovoLog: Different formulations of insulin used to treat diabetes.
More drugs will be added to the negotiation list in future years, expanding the potential for savings across a wider range of treatments.
Major Relief: The $2,000 Cap on Drug Costs
While the negotiated drug prices start in 2026, another critical cost-saving measure actually begins a year earlier, in 2025. This change will have a massive impact on spending for beneficiaries in 2026 and beyond.
Starting in 2025, there will be a $2,000 annual cap on what you have to pay out-of-pocket for prescription drugs covered under your Medicare Part D plan.
How the Out-of-Pocket Cap Works
Currently, there is no hard cap on what a beneficiary might have to spend on drugs in a year. After reaching a “catastrophic coverage” threshold, they still have to pay 5% of the cost of their drugs, which can add up to thousands of dollars for those on expensive medications.
The new rule eliminates this 5% coinsurance. Once your spending on deductibles, copayments, and coinsurance reaches $2,000 for the year, you will pay $0 for your covered prescription drugs for the rest of that year. This provides a predictable and much lower ceiling on annual drug expenses.
A New Way to Pay: Spreading Costs Over the Year
To help with budgeting, another feature called the Medicare Prescription Payment Plan also starts in 2025. This program allows you to “smooth” your costs by paying your out-of-pocket expenses in fixed monthly installments throughout the year, rather than facing large, unpredictable bills at the pharmacy. This makes it easier to manage the path to reaching the $2,000 cap without breaking your budget.
Who Is Eligible for These Medicare Savings?
This is the most important question, and the answer is straightforward.
You are eligible for these new cost-saving benefits if you are enrolled in a Medicare prescription drug plan (Part D).
This includes anyone who has:
- A standalone Medicare Part D Prescription Drug Plan (PDP).
- A Medicare Advantage plan that includes prescription drug coverage (MA-PD).
There is no separate application process to qualify for the $2,000 cap or the lower prices on negotiated drugs. These changes are built directly into the structure of the Medicare Part D program. If you have Part D coverage, these benefits will automatically apply to your plan starting in 2025 and 2026.
The key is to ensure you are enrolled in a Part D plan that best fits your needs, especially considering the specific medications you take. During the annual Open Enrollment period, you can compare plans to see how these new rules will affect your total costs.
Frequently Asked Questions
Do I need to sign up for a special program to get these discounts? No. The $2,000 out-of-pocket cap and the negotiated drug prices are not separate programs. They are improvements to the standard Medicare Part D benefit. As long as you are enrolled in a Part D plan, these changes will automatically apply.
Will the list of negotiated drugs grow? Yes. CMS will select up to 15 more Part D drugs for negotiation for 2027, another 15 for 2028 (including some Part B drugs), and up to 20 more drugs for each year after that. The program is designed to expand over time.
How will I know what the new price of a negotiated drug is? The new, lower prices will be reflected in the copayments and coinsurance you pay at the pharmacy starting in 2026. Your plan’s documents and the Medicare Plan Finder tool will be updated to show these new costs during the Open Enrollment period before 2026.